Biotechnology

AI Maverick Launches Enhanced Prospecting Platform to Deliver Human Like Outreach - No SDR Team Required

July 17, 2025 7:00 AM

AI Maverick Intel, Inc. (OTCID:BINP) ("AI Maverick" or the "Company") today announces the full rollout of its next-generation prospecting engine-enabling revenue teams to research, engage, and qualify prospects at scale without the need for additional headcount. Key Capabilities Comprehensive contact intelligence - Millions of structured and unstructured data points are aggregated into unified profiles, surfacing job changes, buying signals, and...

Read more

Lobe Sciences Ltd. Announces Debt Settlement

July 16, 2025 9:55 PM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases, today announced that it has settled an outstanding debt of CAD$11,596.22 owed to Gibbsons P.C. for legal services previously provided to the Company. In satisfaction of this obligation, Lobe has issued 546,206 common shares of the Company to Gibbson Law P.C. at a deemed price of CAD$0.02123...

Read more

Immortal Dragons Launches $40M Longevity Fund to Support Radical Life Extensions

July 16, 2025 5:10 PM

Immortal Dragons, a purpose-driven longevity fund headquartered in Singapore, today announced its unique approach to investing in radical life extension technologies. With $40 million in assets under management (AUM), Immortal Dragons is poised to redefine how capital fuels scientific breakthroughs in longevity and healthspan. At its core, Immortal Dragons is driven by a profound philosophy: to view aging and death not as inevitability, but as...

Read more

Aspira Women's Health Announces Appointment of Jane Pine Wood to the Board of Directors

July 15, 2025 4:01 PM

Aspira Women's Health Inc. ("Aspira" or the "Company") (QTCQB:AWHL), an AI enhanced bio-analytical based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced the appointment of Jane Pine Wood to the Board of Directors, effective July 11, 2025. "We are pleased to welcome Jane Pine Wood to the Board of Directors," said Jack Fraser, Chairman of the Board...

Read more

BioLumic Brings Food-System Pioneers to Scientific Advisory Group, Deepening World-Class Expertise in Light-Programmed Seed Traits

July 15, 2025 10:15 AM

BioLumic, the only agricultural biotechnology company that programs seed traits using light, today announced the appointment of Dr. Howard-Yana Shapiro, distinguished senior fellow at CIFOR-ICRAF, and Dr. Jeremy Hill, chief science & technology officer at Fonterra Co-operative Group Limited, to its Scientific Advisory Group. Dr. Shapiro and Professor Hill join founding members Professor Mark Tester - internationally renowned for pioneering the...

Read more

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

July 15, 2025 3:50 AM

AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1...

Read more

"Athos Omics AI": A Revolutionary Software Platform to Analyze Omics Data Across Industries

July 14, 2025 11:00 AM

Athos Therapeutics, Inc. ("Athos"), an AI software and clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, announced the launch of a new website that details "Athos Omics AI" their novel and impactful data platform for analyzing omics data across industries. Omics analysis refers to processing large-scale biological information derived from genes,...

Read more

Alligator Bioscience Comments on Henlius Dosing First Patient in the US in Phase 3 Trial of HLX22 in Gastric Cancer

July 14, 2025 9:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that it has dosed the first patient in the United States in its global Phase 3 clinical trial (NCT06532006) of HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive metastatic gastric and gastroesophageal junction (GEJ) cancer. HLX22 is an anti-HER2 monoclonal antibody being developed by...

Read more

Announcement from Extra General Meeting in Biovica International AB

July 14, 2025 5:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Today on 14 July 2025 the extra general meeting of Biovica International AB (the "Company") was held, and the following resolutions were passed by the meeting. Amendments of the articles of association The extra general meeting resolved, for the purpose of carrying out the below resolutions, to increase the limits for share capital in the articles of association from a minimum of SEK...

Read more

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

July 10, 2025 3:10 PM

IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer's, the Company's proprietary AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear. MINT-AD leverages diverse data sources including brain scans, genetics, lifestyle,...

Read more

Canary Cure Therapeutics Unveils Breakthrough Human Cell Data for Next-Generation Obesity Therapy, CCT-217, Demonstrating Muscle-Building Fat Loss and Paving Path to Clinic

July 10, 2025 10:00 AM

Canary Cure Therapeutics (Canary), a pioneering biopharmaceutical company, today announced groundbreaking human cell data for its lead therapeutic candidate, CCT-217. The findings confirm a unique mechanism that promotes rapid, selective fat loss while preserving and building muscle. This strong human and preclinical evidence de-risks the clinical path for a transformative, twice-yearly treatment for obesity, with Phase 1 trials targeted for...

Read more

Alligator Bioscience AB Reports Financial Results for Q2 2025 and Provides a Business Update

July 10, 2025 2:20 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) "With key regulatory and manufacturing milestones achieved for mitazalimab and strengthened financials, we remain focused on identifying a strategic partner and initiating Phase 3. During the quarter, we successfully completed GMP manufacturing and received clear regulatory feedback from both the FDA and EMA-confirming dose, trial design and paediatric waiver-further strengthening the program's...

Read more

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

July 9, 2025 8:00 AM

Renovaro Inc. (NASDAQ:RENB), an AI-driven precision medicine company, today announced that senior debt holders have agreed to convert an aggregate of approximately $9.7 million of outstanding senior debt into convertible debt which they have elected to convert into equity. Under the terms of the agreement, the Company will issue an aggregate of approximately 53.6 million shares of common stock at a conversion price of $0.30 per share. This share...

Read more

Faron Announces Acceptance of Two Studies Involving Bexmarilimab, One of Them as an Oral Presentation, at the 19th International Congress of Immunology (IUIS) 2025

July 9, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - The oral presentation and poster showcase bexmarilimab's dual attack on cancer with new mechanistic data from clinical studies TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, today announced the acceptance of two studies involving its lead candidate, bexmarilimab,...

Read more

Vibrant Wellness Launches Redesigned Gut Microbiome Test With Broader Microbial and Metabolic Insights

July 8, 2025 10:30 AM

Vibrant Wellness, a global CAP-accredited biotech lab testing company, has improved its widely used Gut Zoomer panel. Vibrant's upgraded microbiome panel now features expanded microbial and metabolite coverage, a refined report format, and a multi-method detection platform for deeper clinical insights. The Gut Zoomer combines PCR, sandwich ELISA, LC-MS/MS, and protein microarray technologies to evaluate the gut ecosystem from multiple angles....

Read more

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

July 8, 2025 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that Bnei Zion Medical Center has commenced patient dosing in an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the...

Read more

Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease

July 8, 2025 12:01 AM

Lobe Sciences Ltd. (CSE:LOBE), (OTCQB:LOBEF), (FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases, today announced that the European Patent Office has officially validated the company's European Patent EP4117446 as a Unitary Patent. Titled "A Composition Comprising Docosahexaenoic Acid… for Sickle Cell Disease Treatment," the patent covers novel formulations combining DHA and...

Read more

Faron Pharmaceuticals Ltd: Director Dealing

July 2, 2025 6:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Tuomo Pätsi, Non-Executive Chairman of the Company, acquired 21,500 ordinary shares in Faron at price of €2.435 per share on 30 June 2025. Following this purchase, Mr. Pätsi directly holds 53,265 ordinary shares in the Company, representing 0.05 per cent. of the voting rights...

Read more

Imagene AI Hits $45M in Total Funding After Completing $23M Series B Led by Larry Ellison

July 1, 2025 8:00 AM

Imagene AI, a pioneer in multi‑modal foundation models for precision medicine, today announced the successful close of a $23 million Series B financing round led by Oracle Chairman and CTO Larry Ellison. This latest infusion brings Imagene AI's total capital raised to $45 million under terms that reflect the company's accelerating momentum and expanding strategic footprint. The round also included participation from existing investor Aguras...

Read more

180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets

July 1, 2025 7:30 AM

180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector, today announced two significant value enhancements to its existing, legacy intellectual property ("IP") portfolio-reinforcing part of the Company's strategy relating to continuing to build shareholder value through scientific innovation and patent protection for legacy IP assets. These new...

Read more